Meropenem Combino (Meropenem Trihydrate)

• Meropenem is used to treat serious bacterial infections across several organ systems.
• Complicated intra‑abdominal infections: effective against mixed‑flora infections of the abdomen in hospitalized patients.
• Complicated urinary tract infections: eradicates resistant Gram‑negative pathogens causing pyelonephritis and cystitis.
• Skin and soft tissue infections: resolves severe cellulitis and necrotizing infections caused by susceptible organisms.
• Meningitis: penetrates the cerebrospinal fluid to treat bacterial meningitis.
• Sepsis: provides broad‑spectrum coverage for life‑threatening bloodstream infections.

• Meropenem binds irreversibly to penicillin‑binding proteins (PBPs) on the bacterial cell wall, inhibiting the final transpeptidation step of peptidoglycan synthesis. This disruption weakens the cell wall, leading to osmotic instability, cell lysis and bacterial death. The drug is stable against most β‑lactamases, giving it broad activity against Gram‑negative, Gram‑positive and anaerobic organisms. It is administered intravenously, achieving high plasma concentrations that exceed the minimum inhibitory concentrations of target pathogens.

Meropenem may cause a range of adverse reactions, ranging from mild to severe.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: may be watery and self‑limiting.
• Infusion site reactions: redness, pain or swelling at the injection site.
• Rash: non‑specific skin eruptions.
• Headache: transient and usually resolves after treatment.
• Elevated liver enzymes: mild, transient increase in hepatic transaminases.

Serious or Rare Side Effects

• Seizures: especially in patients with renal impairment or CNS disorders.
• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Clostridioides difficile‑associated colitis: risk of severe diarrhea and colitis.
• Severe neutropenia: marked reduction in white blood cells.
• Acute renal failure: worsening kidney function in susceptible individuals.
• Stevens‑Johnson syndrome: rare but life‑threatening skin reaction.

• When using Meropenem, clinicians should consider several safety measures.
• Renal function: adjust dose in patients with impaired renal function.
• Allergy: avoid in patients with known hypersensitivity to carbapenems or other β‑lactams.
• Seizure risk: monitor patients with central nervous system disorders or high‑dose therapy.
• Pregnancy: use only if potential benefit justifies potential risk to the fetus.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Meropenem can interact with other medicines, requiring careful review.

Major Interactions (Avoid)

• Valproic acid: may increase risk of seizures.
• Probenecid: may reduce renal clearance of meropenem.
• Cytotoxic chemotherapy: may increase toxicity.

Moderate Interactions (Monitor Closely)

• Loop diuretics: may affect renal function.
• Aminoglycosides: additive nephrotoxicity.
• Anticoagulants (e.g., warfarin): may alter INR and bleeding risk.